Novartis Q2 2026 sales modestly beat forecasts

 

 as net profit falls 19% and it reiterates low single-digit 2026 sales growth outlook

• Q2 net income was $3.26 billion, with adjusted EPS of $2.41.
• Q2 revenue reached $14.41 billion, exceeding analyst estimates for the quarter.
• Net profit declined 19% in Q2 on higher interest and tax costs.

https://finviz.com/stock?t=NVS&p=d